These adjustments were applied to data from a randomized double-blind concurrent trial ( SPD@-@ ) that established the efficacy and safety of lisdexamfetamine dimesylate ( LDX ) in children and adolescents with attention-deficit/hyperactivity disorder ( ADHD ) .